CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Get Free Report) shares were down 0.8% on Tuesday . The company traded as low as $3.85 and last traded at $3.89. Approximately 9,874 shares were traded during trading, an increase of 5% from the average daily volume of 9,436 shares. The stock had previously closed at $3.92.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on CLGN shares. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a report on Wednesday, August 21st.
View Our Latest Research Report on CollPlant Biotechnologies
CollPlant Biotechnologies Price Performance
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last announced its earnings results on Tuesday, August 20th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.70 million. CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. As a group, analysts anticipate that CollPlant Biotechnologies Ltd. will post -1.44 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. boosted its position in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Free Report) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 564,360 shares of the company’s stock after purchasing an additional 33,905 shares during the period. Pinnacle Associates Ltd. owned 4.93% of CollPlant Biotechnologies worth $2,805,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.69% of the company’s stock.
CollPlant Biotechnologies Company Profile
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
See Also
- Five stocks we like better than CollPlant Biotechnologies
- Consumer Staples Stocks, Explained
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Top Biotech Stocks: Exploring Innovation Opportunities
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- P/E Ratio Calculation: How to Assess Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.